Neuronetics (STIM) Stock Price, News & Analysis

Company Overview

Neuronetics, Inc. is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation. The company’s platform is designed for use in outpatient clinics, hospitals and psychiatry practices across the United States. Neuronetics maintains a specialized field sales force and collaborates with key channel partners to support physician training, patient education and therapy delivery. In addition to its commercial activities, the company continues to explore new indications and protocol optimizations to expand its therapeutic offerings.

Guided by a leadership team with deep experience in medical devices and neuroscience, Neuronetics strives to improve patient outcomes through research, regulatory engagement and post-market data collection. The company’s ongoing efforts include refining device features, enhancing treatment compliance and evaluating the use of its technology in other neuropsychiatric conditions. Neuronetics is publicly traded on the Nasdaq under the symbol STIM.

Key Stats

• Today's Range: $1.97 to $2.19
• 50-Day Range: $1.22 to $2.17
• 52-Week Range: $0.80 to $4.85
• Volume: 1.25 million shs
• Average Volume: 2.14 million shs
• Market Capitalization: $137.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Hold

Neuronetics Stock Analysis - MarketRank™

Neuronetics scored higher than 52% of companies evaluated by MarketBeat, and ranked 447th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Neuronetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Neuronetics has a consensus price target of $3.00, representing about 42.9% upside from its current price of $2.10.

Amount of Analyst Coverage

Neuronetics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Neuronetics are expected to grow in the coming year, from ($0.49) to ($0.35) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neuronetics is -3.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neuronetics is -3.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neuronetics has a P/B Ratio of 5.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

17.18% of the float of Neuronetics has been sold short.

Short Interest Ratio / Days to Cover

Neuronetics has a short interest ratio ("days to cover") of 4.52.

Change versus previous month

Short interest in Neuronetics has recently increased by 16.37%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neuronetics does not currently pay a dividend.

Dividend Growth

Neuronetics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.35

News Sentiment

Neuronetics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 9 news articles for Neuronetics this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for STIM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

3 people have added Neuronetics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 3.8 / 5
• Insider Trading: Acquiring Shares

Net Insider Buying

Over the last three months, insiders have purchased a net $2,161,818.00 in company stock, which represents 1.4795% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Neuronetics insiders have bought 801.90% more of their company's stock than they have sold. Specifically, they have bought $2,431,406.00 in company stock and sold $269,588.00 in company stock.

Percentage Held by Insiders

8.40% of the stock of Neuronetics is held by insiders.

Percentage Held by Institutions

53.59% of the stock of Neuronetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

STIM Stock Analysis - Frequently Asked Questions

How have STIM shares performed this year?

Neuronetics' stock was trading at $1.38 on January 1st, 2026. Since then, STIM stock has increased by 52.2% and is now trading at $2.10.

How were Neuronetics' earnings last quarter?

Neuronetics, Inc. (NASDAQ:STIM) posted its earnings results on Tuesday, May, 5th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. The firm had revenue of $34.45 million for the quarter, compared to the consensus estimate of $34.17 million. Neuronetics had a negative net margin of 26.15% and a negative trailing twelve-month return on equity of 121.26%.
Read the conference call transcript.

When did Neuronetics IPO?

Neuronetics (STIM) raised $82 million in an IPO on Thursday, June 28th 2018. The company issued 5,500,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Who are Neuronetics' major shareholders?

Neuronetics' top institutional investors include AdvisorShares Investments LLC (0.89%), Citizens Financial Group Inc. RI (0.16%) and IMC Chicago LLC (0.04%). Insiders that own company stock include Keith J Sullivan, William Andrew Macan, Steven Pfanstiel, Robert Cascella, Stephen Furlong and Glenn P Muir.
View institutional ownership trends.

How do I buy shares of Neuronetics?

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Neuronetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neuronetics investors own include Gilead Sciences (GILD), SCYNEXIS (SCYX), Pfizer (PFE), GE Aerospace (GE), Intel (INTC), Bank of America (BAC) and Nokia (NOK).

Company Calendar

• Last Earnings: 5/05/2026
• Today: 5/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:STIM
• CIK: 1227636
• Web: www.neurostar.com
• Phone: (610) 640-4202
• Fax: 610-640-4206
• Employees: 180
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Neuronetics: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: +51.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39 million
• Net Margins: -26.15%
• Pretax Margin: -26.24%
• Return on Equity: -121.26%
• Return on Assets: -27.67%

Debt

• Debt-to-Equity Ratio: 2.51
• Current Ratio: 2.02
• Quick Ratio: 1.87

Sales & Book Value

• Annual Sales: $149.16 million
• Price / Sales: 0.93
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.38 per share
• Price / Book: 5.22

Miscellaneous

• Outstanding Shares: 69,580,000
• Free Float: 63,735,000
• Market Cap: $138.12 million
• Optionable: Optionable
• Beta: 1.13